ERBB2 and breast cancer: Ongoing follow-up of this cohort of patients is planned to further understand the shifting practice patterns of adjuvant therapy in HER2-positive breast cancer with the availability of new agents and potentially validation of patient selection strategies to maximize benefit and minimize toxicity for patients less likely to experience recurrence.